These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31899993)

  • 1. Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects.
    Rajendra A; Noronha V; Joshi A; Patil VM; Menon N; Prabhash K
    Expert Rev Anticancer Ther; 2020 Jan; 20(1):17-29. PubMed ID: 31899993
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
    Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
    J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatment options for metastatic head and neck cancer.
    Price KA; Cohen EE
    Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab in the first-line treatment of advanced head and neck cancer.
    de Sousa LG; Ferrarotto R
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1321-1331. PubMed ID: 34689660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
    Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
    Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].
    Zech HB; Laban S; Schafhausen P; Bussmann L; Betz C; Busch CJ
    HNO; 2019 Dec; 67(12):898-904. PubMed ID: 31701170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
    Desilets A; Soulières D
    Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
    Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
    Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
    Takahashi S; Oridate N; Tanaka K; Shimizu Y; Fujimoto Y; Matsumoto K; Yokota T; Yamazaki T; Takahashi M; Ueda T; Hanai N; Yamaguchi H; Hara H; Yoshizaki T; Yasumatsu R; Nakayama M; Shiga K; Fujii T; Mitsugi K; Takahashi K; Nohata N; Gumuscu B; Swaby RF; Tahara M
    Int J Clin Oncol; 2022 Dec; 27(12):1805-1817. PubMed ID: 36264378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
    Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
    Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
    Motai R; Sawabe M; Kadowaki S; Sasaki E; Nishikawa D; Suzuki H; Beppu S; Terada H; Hanai N
    Int J Clin Oncol; 2021 Jul; 26(7):1188-1195. PubMed ID: 33821363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
    Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.
    Yu X; Su X; Fang L; Zhang H; Chen X; Pu Y; Liu H; Guo R
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1391-1401. PubMed ID: 36181527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Sun L; Cohen RB; Dimitrios Colevas A
    Oral Oncol; 2024 Nov; 158():106997. PubMed ID: 39159526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
    Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
    J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.